A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2 positive advanced gastric cancer - HIGHSOX study

Cancer Institute Hospital Japanese Foundation For Cancer Research0 个研究点目标入组 75 人开始时间: 2015年5月18日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) could not administrate S-1,Oxaliplatin,and Trastuzumab 2)pregnant and/or nursing women or men who wish to have children in future 3)with actuve infectious disease 4)HBs antigen positive 5)with a histroy or current symptoms of heart failure, uncontrollable arrhythmia,angina pectoris,valvular disease,and uncontrollable hypertension 6)with interstitial pneumonia, pulmonary fibrosis, heart hailure, renal failure, hepatic failure, uncontrollable diabetes mellitus 7)with dyspnea at rest 8)with active bleeding from gastric cancer/ulcer 9)with severe diarrhea(over 4 times a day or watery diarrhea) 10)with severe sensory neuropathy 11)with active double cancers excluding carcinoma in situ and/or prior curative cancer with relapse free for more than 5 years 12)under meditation of flucytosine, phenytoin,or warfarin 13) under continuous meditation of steroids 14)judged to be unfit to participate in this study by investigater

发起方

Cancer Institute Hospital Japanese Foundation For Cancer Research